EPO Biomarkers Market size and Key Trends in terms of volume and value 2016-2026
Erythropoietin is special type of protein biomarker, also known as a growth factor. It acts by the stimulating the bone marrow to manufacture red blood cells. There are five different types of erythropoietin biomarkers such as epoetin alfa, epoetin beta, epoetin zeta, epoetin theta and darbepoetin alfa. Erythropoietin is mostly administered subcutaneously as an alternative to iron supplements. Erythropoietin used in human beings is also known as recombinant human erythropoietin (rHuEPO). Commercially available rHuEPO has the same 165 amino acid sequence as available in naturally occurring hormone but the level of glycosylation in rHuEPO depends on the testing method used. Growing global incidence of renal diseases and cancers is expected to create a marked increase in use of EPO biomarkers.
Erythropoietin is special type of protein biomarker, also known as a growth factor. It acts by the stimulating the bone marrow to manufacture red blood cells. There are five different types of erythropoietin biomarkers such as epoetin alfa, epoetin beta, epoetin zeta, epoetin theta and darbepoetin alfa. Erythropoietin is mostly administered subcutaneously as an alternative to iron supplements. Erythropoietin used in human beings is also known as recombinant human erythropoietin (rHuEPO). Commercially available rHuEPO has the same 165 amino acid sequence as available in naturally occurring hormone but the level of glycosylation in rHuEPO depends on the testing method used. Growing global incidence of renal diseases and cancers is expected to create a marked increase in use of EPO biomarkers.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Report Description<br />
<strong>EPO</strong> <strong>Biomarkers</strong> <strong>Market</strong>: Region-wise Outlook<br />
Consider<strong>in</strong>g all potential geographic regions, <strong>EPO</strong> biomarkers market is segmented <strong>in</strong>to<br />
seven key regions: North America, Lat<strong>in</strong> America, Eastern Europe, Western Europe,<br />
Japan, Asia Pacific <strong>and</strong> Middle East & Africa. North America is been dom<strong>in</strong>at<strong>in</strong>g <strong>in</strong> the<br />
<strong>EPO</strong> biomarkers due to rise <strong>in</strong> acceptance for bio-similar weakly followed by Western <strong>and</strong><br />
Eastern Europe, Asia Pacific has a dom<strong>in</strong>at<strong>in</strong>g presence <strong>in</strong> <strong>EPO</strong> biomarker market <strong>and</strong><br />
most <strong>of</strong> the key players are locally produc<strong>in</strong>g the <strong>EPO</strong> biomarkers, that is enhanc<strong>in</strong>g their<br />
market share <strong>and</strong> product reach. There is a good opportunity for Japan <strong>in</strong> <strong>EPO</strong><br />
biomarker market. The emerg<strong>in</strong>g regions <strong>in</strong> Asia Pacific, Middle East <strong>and</strong> Africa holds<br />
promis<strong>in</strong>g future for rise <strong>in</strong> <strong>EPO</strong> biomarker market, due to <strong>in</strong>crease <strong>in</strong> awareness towards<br />
the chronic disease <strong>and</strong> <strong>in</strong>crease <strong>in</strong> population simultaneously.<br />
<strong>EPO</strong> <strong>Biomarkers</strong> <strong>Market</strong>: <strong>Key</strong> Players<br />
Sh<strong>and</strong>ong Kex<strong>in</strong>g Bioproducts Co., Ltd., Amgen Inc., Ranbaxy Laboratories Ltd, Johnson &<br />
Johnson, Roche Hold<strong>in</strong>g AG, Sigma-Aldrich, Thermo Fisher Scientific, Hospira Inc., Biocon,<br />
Teva Pharmaceutical Industries Ltd.,<br />
Browse full report: http://www.futuremarket<strong>in</strong>sights.com/reports/epo-biomarkersmarket
Change language